Why the study?
Symptom-based follow-up is ineffective for antineoplastic cardiotoxicity, and early detection of myocardial damage is critical to prevent damage and improve prognosis in cancer survivors.
An integrated multimodality approach using advanced imaging and biomarkers is crucial for the early detection of chemotherapy-induced cardiotoxicity to prevent irreversible heart failure.
Answers are grounded in this paper and cite their sources.
Early detection of myocardial damage may improve outcomes in cancer survivors; leaves open optimal monitoring techniques pending higher-level evidence.
Cardiovascular diseases are possible complications of antineoplastic treatment and may lead to premature morbidity and mortality among cancer survivors. A symptom-based follow-up is ineffective, and there are growing evidences that early detection of myocardial damage in patients treated with antineoplastic drugs is the key point to prevent the occurrence of damage and improve the prognosis of these patients. Different techniques have been proposed to monitor cardiac function in oncologic patients such as cardiac imaging (echocardiography, nuclear imaging, and cardiac magnetic resonance) and biomarkers (troponin and natriuretic peptides). The European Association of Cardiovascular Imaging/American Society of Echocardiography consensus document encourages an integrated approach to early detect cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Novo et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: